loading
Schlusskurs vom Vortag:
$0.25
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$N/A
Einnahmen:
$257.55M
Nettoeinkommen (Verlust:
$11.95M
KGV:
0.00
EPS:
0.91
Netto-Cashflow:
$-9.39M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-93.26%
1-Tages-Spanne:
Value
$0.00
$0.00
1-Wochen-Bereich:
Value
$0.00
$0.00
52-Wochen-Spanne:
Value
$0.00
$3.725

Eagle Pharmaceuticals Inc Stock (EGRX) Company Profile

Name
Firmenname
Eagle Pharmaceuticals Inc
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
0
Name
Twitter
Name
Nächster Verdiensttermin
2025-08-29
Name
Neueste SEC-Einreichungen
Name
EGRX's Discussions on Twitter

Compare EGRX vs TAK, ZTS, HLN, TEVA, UTHR

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
EGRX
Eagle Pharmaceuticals Inc
0.00 0 257.55M 11.95M -9.39M 0.91
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
18.22 57.12B 29.85B 776.90M 4.35B 0.2408
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
125.96 53.16B 9.47B 2.67B 2.28B 6.0218
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.47 47.25B 14.54B 2.22B 2.58B 0.4879
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
32.91 37.59B 17.41B 1.43B 1.00B 1.2182
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
490.21 21.85B 3.13B 1.27B 1.12B 26.39

Eagle Pharmaceuticals Inc Stock (EGRX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2021-04-07 Fortgesetzt RBC Capital Mkts Outperform
2018-11-01 Herabstufung Cantor Fitzgerald Overweight → Neutral
2018-10-31 Herabstufung Piper Jaffray Overweight → Neutral
2018-03-21 Bestätigt Mizuho Underperform
2017-11-09 Bestätigt RBC Capital Mkts Outperform
2017-09-06 Bestätigt Mizuho Underperform
2017-07-27 Bestätigt Mizuho Underperform
2017-07-27 Bestätigt RBC Capital Mkts Outperform
2017-05-09 Bestätigt RBC Capital Mkts Outperform
2017-01-09 Herabstufung Mizuho Neutral → Underperform
2016-11-16 Herabstufung Mizuho Buy → Neutral
2016-11-03 Hochstufung Mizuho Neutral → Buy
2016-11-03 Bestätigt RBC Capital Mkts Outperform
2016-10-26 Bestätigt Mizuho Buy
2016-08-16 Bestätigt Mizuho Neutral
2016-06-20 Herabstufung Mizuho Buy → Neutral
2016-05-10 Bestätigt RBC Capital Mkts Outperform
2016-03-18 Bestätigt Mizuho Buy
2016-02-26 Bestätigt Mizuho Buy
2015-12-09 Eingeleitet Mizuho Buy
2015-07-29 Bestätigt Piper Jaffray Overweight
Alle ansehen

Eagle Pharmaceuticals Inc Aktie (EGRX) Neueste Nachrichten

pulisher
Feb 23, 2026

Eagle Point Announces Strong Year of Performance with 2025 Year-End Review - Yahoo Finance

Feb 23, 2026
pulisher
Feb 23, 2026

American Eagle to Participate in PDAC 2026 and Ore Day VIP Investor Lunch - Yahoo Finance

Feb 23, 2026
pulisher
Feb 18, 2026

Eagle Health Investments LP Sells 22,400 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Feb 18, 2026
pulisher
Feb 18, 2026

Eagle Health Investments LP Sells 84,600 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat

Feb 18, 2026
pulisher
Feb 17, 2026

Wall Street Bullish on ​Agnico Eagle Mines (AEM) After FQ4 Results - Yahoo Finance

Feb 17, 2026
pulisher
Feb 17, 2026

Is Trending Stock American Eagle Outfitters, Inc. (AEO) a Buy Now? - Yahoo Finance

Feb 17, 2026
pulisher
Feb 17, 2026

CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company's Recently Initiated Strategic Transformation - Eagle-Tribune

Feb 17, 2026
pulisher
Jan 28, 2026

Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development - eagletribune.com

Jan 28, 2026
pulisher
Jan 27, 2026

Deal Watch: Kuva Labs To Go Public Via Merger With Licensing Partner Lisata - Citeline News & Insights

Jan 27, 2026
pulisher
Jan 17, 2026

Eagle Pharmaceuticals (NASDAQ:EGRX) Stock Passes Below Two Hundred Day Moving Average – Here’s What Happened - Defense World

Jan 17, 2026
pulisher
Jan 16, 2026

Agnico Eagle Mines Limited $AEM Shares Acquired by Campbell & CO Investment Adviser LLC - Defense World

Jan 16, 2026
pulisher
Jan 14, 2026

Eagle Pharmaceuticals Announces Divestiture Of Barhemsys - TradingView

Jan 14, 2026
pulisher
Jan 14, 2026

Eagle Pharmaceuticals Announces Divestiture of Barhemsys - The Manila Times

Jan 14, 2026
pulisher
Jan 14, 2026

Only FDA-approved post-surgery nausea drug shifts to new owner - Stock Titan

Jan 14, 2026
pulisher
Jan 12, 2026

Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound - Eagle-Tribune

Jan 12, 2026
pulisher
Jan 08, 2026

GoodRx Launches RxSmartSaver at Giant Eagle Pharmacies - Yahoo Finance

Jan 08, 2026
pulisher
Jan 06, 2026

Top Research Reports for JPMorgan Chase, RTX & Applied Materials - TradingView

Jan 06, 2026
pulisher
Jan 04, 2026

Aadi Bioscience (NASDAQ:AADI) vs. Eagle Pharmaceuticals (NASDAQ:EGRX) Head to Head Survey - Defense World

Jan 04, 2026
pulisher
Jan 01, 2026

Eagle Pharmaceuticals (NASDAQ:EGRX) Stock Price Crosses Above Fifty Day Moving Average – Here’s What Happened - Defense World

Jan 01, 2026
pulisher
Dec 29, 2025

Eagle Point Credit Company Inc. Announces Full Redemption of the 8.00% Series F Term Preferred Stock Due 2029 - Yahoo Finance

Dec 29, 2025
pulisher
Dec 26, 2025

Pemetrexed Market Industry Forecast 2025-2032 Highlights - openPR.com

Dec 26, 2025
pulisher
Dec 24, 2025

HALPER SADEH LLC ENCOURAGES EAGLE PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - The Malaysian Reserve

Dec 24, 2025
pulisher
Dec 18, 2025

Talon Metals to Acquire Lundin Mining's Eagle Mine and Humboldt Mill Operations, Creating a Multi-Asset U.S. Nickel-Copper Company - Yahoo Finance

Dec 18, 2025
pulisher
Dec 15, 2025

Amphastar Announces FDA Approval for Teriparatide Injection - Eagle-Tribune

Dec 15, 2025
pulisher
Dec 12, 2025

Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome - Eagle-Tribune

Dec 12, 2025
pulisher
Dec 11, 2025

DHIL Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Diamond Hill Investment Group, Inc. is Fair to Shareholders - Business Wire

Dec 11, 2025
pulisher
Dec 09, 2025

Critical Review: NexImmune (NASDAQ:NEXI) and Eagle Pharmaceuticals (NASDAQ:EGRX) - Defense World

Dec 09, 2025
pulisher
Dec 07, 2025

Halper Sadeh LLC Encourages Eagle Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights - The AI Journal

Dec 07, 2025
pulisher
Dec 06, 2025

Reviewing Eagle Pharmaceuticals (NASDAQ:EGRX) and Bio-Path (NASDAQ:BPTH) - Defense World

Dec 06, 2025
pulisher
Dec 03, 2025

EB Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Eventbrite, Inc. is Fair to Shareholders - Business Wire

Dec 03, 2025
pulisher
Dec 03, 2025

Eagle Pharmaceuticals (NASDAQ:EGRX) Share Price Crosses Below Two Hundred Day Moving Average – Here’s What Happened - Defense World

Dec 03, 2025
pulisher
Dec 03, 2025

Marvell Posts Strong Q3 Earnings, Joins American Eagle, Microchip Technology, Box And Other Big Stocks Moving Higher On Wednesday - Benzinga

Dec 03, 2025
pulisher
Nov 26, 2025

Galectin Therapeutics: NAVIGATE Data Validates The Fibrosis Thesis - Seeking Alpha

Nov 26, 2025
pulisher
Nov 25, 2025

Here’s What Boosted Alnylam Pharmaceuticals (ALNY) in Q3 - Insider Monkey

Nov 25, 2025
pulisher
Nov 24, 2025

ACA Pharma Announces Major Expansion of RYANODEX® Territory Outside the United States - NEWS CHANNEL NEBRASKA- Northeast

Nov 24, 2025
pulisher
Nov 22, 2025

Eagle Pharmaceuticals (NASDAQ:EGRX) Stock Price Passes Below 200 Day Moving Average – What’s Next? - Defense World

Nov 22, 2025
pulisher
Nov 21, 2025

Vanda Pharmaceuticals: Commercial Execution Meets Pipeline Optionality (NASDAQ:VNDA) - Seeking Alpha

Nov 21, 2025
pulisher
Nov 20, 2025

Telomir Pharmaceuticals director Craig Eagle resigns from board - Investing.com

Nov 20, 2025
pulisher
Nov 19, 2025

ACA Pharma Announces 2026 China NPP Group Procurement Priority List for Orphan and Clinically Urgent Drugs - PRWeb

Nov 19, 2025
pulisher
Nov 12, 2025

Antiemetics Drugs Market Size Worth USD 30.63 Billion by 2034 - BioSpace

Nov 12, 2025
pulisher
Nov 03, 2025

U.S. Vasopressin Market Poised for Transformation with - openPR.com

Nov 03, 2025
pulisher
Oct 30, 2025

Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights Plan - The Manila Times

Oct 30, 2025
pulisher
Oct 30, 2025

Eagle Pharma (OTCMKTS: EGRX) extends stockholder rights plan to 2026; $20 exercise - Stock Titan

Oct 30, 2025
pulisher
Oct 29, 2025

Giant Eagle opens new pharmacy in Mt. Washington, filling gap left by Rite Aid - WTAE

Oct 29, 2025
pulisher
Oct 28, 2025

Total debt per share of EAGLE PHARMACEUTICALS INC – OTC:EGRX - TradingView

Oct 28, 2025
pulisher
Oct 28, 2025

Revenue per share of Eagle Pharmaceuticals, Inc. – LS:A1XEDS - TradingView

Oct 28, 2025
pulisher
Oct 27, 2025

Co-Diagnostics Signs Definitive Agreement with Arabian Eagle in the Kingdom of Saudi Arabia to Establish CoMira Diagnostics and Localize Co-Dx™ PCR Platform Across the Middle East - PR Newswire

Oct 27, 2025
pulisher
Oct 24, 2025

Halper Sadeh LLC Encourages Verrica Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire

Oct 24, 2025
pulisher
Oct 22, 2025

Halper Sadeh LLC Encourages Acadia Pharmaceuticals Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire

Oct 22, 2025
pulisher
Oct 21, 2025

Eagle Pharmaceuticals Announces Results of 2025 Annual Meeting of Stockholders - The Manila Times

Oct 21, 2025
pulisher
Oct 21, 2025

Eagle Pharmaceuticals (OTCMKTS: EGRX) posts 82% quorum; directors elected, BDO ratified - Stock Titan

Oct 21, 2025

Finanzdaten der Eagle Pharmaceuticals Inc-Aktie (EGRX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
drug_manufacturers_specialty_generic RDY
$14.28
price up icon 0.21%
$24.44
price down icon 1.77%
drug_manufacturers_specialty_generic RGC
$25.45
price up icon 6.09%
$133.44
price up icon 1.75%
$14.71
price down icon 1.21%
$490.21
price down icon 1.69%
Kapitalisierung:     |  Volumen (24h):